Therapeutic effects of recombinant human interferon α2b combined with acyclovir in children with herpetic angina
Objective To investigate the clinical efficacy of the combination of recombinant human interferon α2b and acyclovir in the children with herpetic angina(HA)and its application value.Methods 108 children with HA were retrospectively selected from January 2022 to December 2022 and divided into monotherapy group(n=54)and combination group(n=54)according to different treatment.Methods The patients in the monotherapy group were treated with acyclovir,and the patients in the combination group were treated with recombinant human interferon α2b combined with acyclovir.The total effective rate,clinical symptoms disappearance time,adverse reactions,myocardial injury,inflammatory factor and immune function levels before and after treatment were compared between the monotherapy group and combination group.Results The total effective rate in the combination group was 96.30%,which was higher than 85.19%in the monotherapy group,showing a statistically significant difference(P<0.05).After trentment for 7 d,the serum myocardial injury index,inflammatory factor level and CD3+in the combination group were lower than those in the monotherapy group,while immunoglobulin A(IgA),immunoglobulin G(IgG),immunoglobulin M(IgM)and CD4+in the combination group were higher than those in the monotherapy group(P<0.05).The incidence of adverse reactions in the combination group was 9.26%,which was no statistically significant compared with 5.56%in the monotherapy group(P>0.05).Conclusion Recombinant human interferon α2b combined with acyclovir is effective therapy in children with HA,which accelerates the process of rehabilitation,alleviates effectively the clinical symptoms,improves the myocardial injury,inhibits the inflammatory response,and enhances the immune function.
herpetic anginarecombinant human interferon α2bacyclovirinflammatory factorsmyocardial injury
万方数据
维普
